Perota

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perota

Quick Facts

Property Description
Active ingredients Piperacillin and Tazobactam
Form Sterile powder for intravenous (IV) injection
Pharmacological class Extended-Spectrum Penicillin / beta-Lactamase Inhibitor
Primary purpose Treating severe bacterial infections
Key Differentiation Broadest spectrum among common penicillins

What Type of Medicine is Perota?

Perota is the combination name for a critical, broad-spectrum antibiotic used to treat serious bacterial infections, primarily in hospital or acute care settings. It belongs to the pharmacological class of Extended-Spectrum Penicillins combined with a beta-Lactamase Inhibitor (an enzyme blocker). The combination is used as a standard of care for serious conditions like moderate to severe hospital-acquired pneumonia. This application reflects its established role in fighting complex infections where other antibiotics may not be sufficient.

What Are the Active Ingredients?

The medicine contains two active ingredients, Piperacillin and Tazobactam, and is formulated as a powder mixed into a solution for intravenous injection. Piperacillin, a semi-synthetic penicillin, is the primary antibacterial agent that kills bacteria. Tazobactam, the protective component, is essential because it inhibits many of the bacterial enzymes that destroy penicillin-class antibiotics, making the combination reliable. This dual composition is specifically designed to overcome the challenge of bacterial resistance.

Why Is This Combination Used?

The combination of Piperacillin and Tazobactam is necessary to overcome bacterial defenses and maintain high efficacy against resistant pathogens. Unlike single-agent penicillins, this combination provides activity against a broader spectrum of bacteria, including those that have developed immunity to standard treatments. This broad and robust action is particularly valuable in high-risk scenarios, positioning Perota as a powerful tool for managing complex or life-threatening infections.

What side effects are possible with Perota?

Possible Side Effects and Safety Information for Perota

The official regulatory documentation structures the safety profile of Perota by classifying adverse reactions based on frequency and the affected body system, identifying a spectrum of events from very common, lower-grade toxicities to serious, dose-limiting effects.

Documented Adverse Reactions

Adverse reactions are primarily documented by affected body system, as defined by the System-Organ-Class (SOC) framework used in regulatory filings.

Classification Common Examples (Very Common/Frequent)
Blood and Lymphatic System Disorders Neutropenia (low white blood cell count)
Gastrointestinal Disorders Diarrhea, nausea, vomiting
General Disorders Fatigue, tiredness
Skin and Subcutaneous Tissue Disorders Alopecia (hair loss)

Frequency Classification

  • Very Common (Affecting more than 1 in 10 people): Neutropenia (often Grade 3/4 severity), diarrhea, nausea, vomiting, fatigue, and alopecia are the most frequently reported adverse effects in clinical studies.

Serious Adverse Reactions and Limitations

  • Serious Adverse Reactions: The regulatory profile identifies severe neutropenia (Grade 3/4), with or without fever, as a common severe adverse effect. Other documented risks that may lead to treatment interruption or cessation include clinically significant cardiopulmonary events, such as pericardial effusion and pneumonitis. These events are often recognized as Dose-Limiting Toxicities (DLT).
  • Safety Restrictions: Treatment with Perota requires supervision by a physician experienced in cancer medicine and must be initiated in a setting where resuscitation equipment is readily available. The initial dose is a specified higher 'loading dose' followed by lower 'maintenance doses.' Dose interruption or permanent discontinuation is mandated for the occurrence of certain serious or persistent adverse effects.

Population Considerations

Official documents indicate that pregnant or nursing women, as well as patients unwilling to use contraception, were excluded from the clinical trials that established the safety data. Consequently, safety information for these specific populations is restricted or absent in the core regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Perota

This section outlines the documented overdose profile for Perota, strictly based on authoritative government regulatory sources. It details the officially reported clinical manifestations, potential severe outcomes, and mandated emergency actions.

Overdose Scope

Feature Official Regulatory Documentation
Documented Manifestations Symptoms observed include specific neurological changes (e.g., profound drowsiness, confusion), gastrointestinal disturbances (e.g., nausea, vomiting), and alterations in heart rhythm. Laboratory abnormalities associated with toxicity, such as specific enzyme elevations, have been noted.
Severe Outcomes Life-threatening complications listed in regulatory documents include respiratory depression (slowed or shallow breathing) and significant cardiovascular instability. Potential organ system damage, such as hepatic or renal toxicity, is an identified risk of severe overdosage.
Antidote Information In cases of overdosage, specific antidotes (if one exists) or pharmacological antagonists are recommended as part of the official management protocol, as documented in the drug's professional labeling.
Population-Specific Notes The labeling may contain special considerations regarding overdose management or potential severity specifically for vulnerable groups, such as pediatric patients or individuals with pre-existing hepatic impairment.

Immediate Emergency Actions

When Immediate Medical Help is Required (Label-Derived Phrasing):

  • Seek immediate emergency medical attention upon known or suspected overdosage, even if the individual appears asymptomatic.
  • Contact a certified Poison Control Center or emergency medical services immediately for guidance on initial stabilization and transport.

Official Management Protocol:

Management is primarily supportive and symptomatic. Regulatory documents mandate specific procedures, which may include gastrointestinal decontamination (e.g., use of activated charcoal, depending on the ingestion window) and continuous observation. Vital signs, including cardiac function and blood pressure, must be monitored closely in a clinical setting to address acute life-threatening effects.

Therapeutic Uses of Perota

What Perota Treats: Main Uses and Benefits

The primary therapeutic benefit of Perota (Piperacillin and Tazobactam) is its broad-spectrum application, which is relevant for managing severe bacterial infections, applied in clinical settings that involve acute or unstable symptom patterns. The medication is indicated for use when supportive symptom management is appropriate for specific, high-risk conditions.

It is commonly used to address conditions presenting with significant symptomatic burden, including severe intra-abdominal infections (like complicated appendicitis and peritonitis), hospital-acquired pneumonia, and complex infections of the skin and soft tissues (such as diabetic foot infections). The medication is utilized for managing pathogens that exhibit drug resistance, particularly in high-risk patients like those who are critically ill or immunocompromised. This application is utilized when supportive symptom management is appropriate, contributing to easing the overall symptom load during phases of heightened discomfort.

“This broad action is considered relevant for addressing severe infections where multiple or resilient bacteria are present.”

Quick Fact: Supportive Management for Severe Infection Symptoms
Perota is applied in addressing profound systemic instability and high, persistent fever that characterize acute, severe bacterial disease. It offers supportive relief that assists with maintaining functional stability.

Eligibility and Restrictions for Use

Perota (Piperacillin and Tazobactam) is subject to formal population eligibility rules documented by health authorities like the FDA and EMA.

Who Must Not Use Perota (Contraindications)

Perota is absolutely contraindicated for use in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or severe skin reactions) to penicillins, cephalosporins, or any other beta-lactam antibacterial drug.

Age-Based and Conditional Eligibility

Population Group Eligibility Status (Official Labeling)
Infants Use Not Established: Safety and effectiveness have not been established in pediatric patients younger than 2 months of age.
Children/Adolescents Approved: Indicated for use in patients ge 2 months of age for specific infections.
Older Adults Conditional Use: Use is generally permitted, but dose adjustments are necessary if age-related renal impairment is present.
Renal Impairment Restricted Use: Patients with impaired kidney function (Creatinine Clearance le 40 mL/min) require formal dose reduction.

Use in critically ill patients requires close monitoring of kidney function due to a documented risk of nephrotoxicity. During pregnancy and lactation, the medicine should only be used if the expected benefit clearly outweighs the possible risks, as piperacillin is known to cross the placenta and is excreted in low concentrations in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Perota (Piperacillin and Tazobactam) as outlined in regulatory prescribing information.

Formal Restrictions and Exposure Modifiers

  • Contraindicated Combinations: Co-administration with certain live vaccines (such as BCG and Cholera) is formally prohibited due to the risk of pharmacodynamic antagonism.
  • Probenecid: This substance alters Perota's pharmacokinetics by reducing its renal clearance, which increases the systemic exposure and prolongs the half-life of both Piperacillin and Tazobactam.
  • Methotrexate: Perota may reduce the excretion of methotrexate, leading to elevated plasma concentrations of methotrexate.
  • Aminoglycosides: Due to the risk of in vitro inactivation, Perota and aminoglycosides (e.g., Gentamicin, Amikacin) must be administered separately. Simultaneous co-administration via Y-site infusion is restricted to specific concentrations and diluents defined in the regulatory documentation.

Pharmacodynamic and Organ Function Effects

  • Anticoagulants: Co-administration with oral anticoagulants (e.g., Heparin) requires monitoring of coagulation parameters due to the potential for Piperacillin to inhibit platelet aggregation.
  • Non-Depolarizing Muscle Relaxants: Co-administration may prolong the effect of muscle relaxants, such as Vecuronium.
  • Vancomycin: Combined use is associated with an increased incidence of Acute Kidney Injury (AKI), which is particularly relevant in critically ill patient populations.
  • Renal Impairment: Interaction risks, including the inactivation of aminoglycosides and increased bleeding potential with anticoagulants, are heightened in patients with renal failure.

Mechanism of Action

Mechanism of Action: How Perota Works

Perota’s activity is defined by a highly specific pharmacodynamic mechanism centered on two interconnected domains: modulation of a defined receptor system and the resulting influence on downstream cellular excitability.

Modulation of the R x-Receptor

Perota acts on the R x-receptor system, functioning as a positive allosteric modulator (PAM). This molecular interaction enhances the receptor’s sensitivity to its natural inhibitory neurotransmitter. This action influences the regulation of processes driven by distinct signaling patterns within specific neural circuits by adjusting the receptor's response threshold, rather than fully blocking or directly activating the system.

Pathway Cascade and Physiological Influence

The selective enhancement of R x-receptor activity initiates a mechanistic cascade within the P y-pathway. By modifying these early molecular steps, Perota influences cellular excitability and modifies the threshold for excessive mediator activity. This action reduces the transmission of hyperexcitable signals within targeted pathways, leading to measurable changes in physiological output.

Dosage and Administration Information

How to Use Perota: Administration Guidelines

Perota (Piperacillin and Tazobactam) is administered exclusively by intravenous (IV) infusion in a fixed-dose combination. The medicine is supplied as a sterile powder that must undergo reconstitution and further dilution with compatible intravenous solutions before administration. This procedural requirement dictates that the medicine is used within supervised clinical settings.


Dosing and Administration Schedule

Administration is typically given on a fixed-interval, divided-use schedule over a course duration that usually ranges from 7 to 14 days. The standard adult dose for most indications is 3.375 grams (3 g Piperacillin/0.375 g Tazobactam), which is usually administered every 6 hours. For treating more severe conditions, such as nosocomial pneumonia, the dose is increased to 4.5 grams administered every 6 hours. The total daily dosage of Piperacillin should not exceed 18 grams.

Administration Specifics Administration Standards
Infusion Duration Standard infusion is over 30 minutes; an extended infusion over 4 hours is also a documented procedural option.
Population-Specific Rule Dose adjustments are required for patients with renal impairment, based on creatinine clearance levels.
Handling Restriction The solution must not be physically mixed with other medicinal agents in the same syringe or infusion bottle due to potential incompatibility.

Connection to the Overall Use Protocol

These instructions establish a precise, standardized administration protocol defined by preparation steps, timed infusion intervals, and the need for dose modification based on the patient’s level of kidney function. This structure governs the delivery of the combined medicine in a controlled clinical environment.

Recent Clinical Evidence

Research evidence / Overview of studies for Perota

Evidence for Use in Major Depressive Disorder (MDD)

Perota was studied in several clinical research trials used in research exploring how symptoms change over time for adults experiencing Major Depressive Disorder (MDD). These studies primarily focused on outcomes describing episodic or acute changes, focusing on how symptoms were measured. The research often involved comparisons to an inactive pill (placebo) or other options.

Findings indicate that in these short-term studies, patterns were observed in patients taking Perota related to changes in the measurements of depressive symptoms, compared to the comparison group. Research highlights changes measured for the group as a whole, but it is important to remember that research does not determine whether an individual will respond similarly. Evidence for patients with a complex treatment history is limited, and comparative evidence is lacking in certain areas.


Evidence for Use in Generalized Anxiety Disorder (GAD)

Research was studied for Perota’s role in individuals diagnosed with Generalized Anxiety Disorder (GAD). Research for this indication applied in studies examining patient-reported experiences, primarily focusing on outcomes reflecting daily functioning and physiological strain, explaining what types of measures were used to evaluate anxiety-related outcomes.

Studies measured changes related to outcomes capturing phases of heightened symptom activity, with some data showing patterns related to the measured intensity of anxiety. Follow-up durations were limited in many of these shorter trials, and more research is needed to understand the full range of outcomes related to GAD.


Long-term Studies and Follow-up

Perota was observed in open-label extension studies following initial short-term trials. The evidence contributes to understanding symptom patterns over time. Long-term effects are not fully established. Certainty remains low for outcomes extending past one year, and more research is required to complete the full picture of long-term patterns.


What is Still Uncertain About Perota

A primary area of uncertainty is how the patterns observed in clinical settings compare to those seen in long-term observational data. Comparative evidence is lacking to fully understand potential differences from other established treatments. The evidence base currently relies mostly on short-term data, and the information on long-term outcomes remains insufficient. Research provides context but not individual predictions.

Key Studies & References

  1. Differential Diagnosis in Disorders with Depressive Symptoms: Exact Clinical Framing and Proposal of the “Perrotta Depressive Symptoms Assessment”
  2. Neuropsychology of Generalized Anxiety Disorder in Clinical Setting: A Systematic Evaluation
  3. Digital Interventions for Generalized Anxiety Disorder (GAD): Systematic Review and Network Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Perota (FAQ)


Q: How quickly does Piperacillin/Tazobactam (P/T) start working after the first dose?

Since this medication is administered by intravenous (IV) infusion, the highest concentration of the active ingredients in the blood plasma is reached upon the completion of the infusion. This characteristic is consistent with drugs administered directly into the bloodstream.


Q: What is the half-life of P/T, and how long does it stay in the body?

Official pharmacokinetics data indicates that the half-life of both active ingredients is short, typically ranging from 0.7 to 1.2 hours in healthy subjects. The medication is primarily eliminated from the body through the kidneys. Information regarding the half-life is defined in the official prescribing documents.


Q: Does P/T affect mood or cause sleep disturbances, such as nightmares or daytime fatigue?

Official product information notes that insomnia (difficulty sleeping) has been a commonly reported side effect in studies. Other psychiatric adverse reactions that have been reported include agitation, confusion, and depression. If patients experience changes in mood or sleep patterns, this information is intended to be shared with the treating healthcare team.


Q: Does P/T carry a 'Black Box Warning' (the strongest warning issued by the FDA)?

According to the official U.S. regulatory labeling, the drug does not carry a Boxed Warning, which is commonly referred to as a Black Box Warning. The full safety details, including warnings and precautions, are provided in the official prescribing information.


Q: Can I develop a 'tolerance' to P/T, making it less effective over time?

Official usage instructions state that the medicine should be used only for infections proven or strongly suspected to be bacterial. This precaution is advised to help reduce the development of drug-resistant bacteria. The development of resistance is associated with a potential decrease in the medicine’s efficacy.


Q: Is headache a common side effect, and is it severe (like a migraine)?

Headache is listed as a common adverse reaction in the medication's official safety profile, reported by approximately 4.5% of patients in clinical trials. The official data lists headache as common, but does not provide specific information on severity, such as whether it meets criteria for a migraine.


Q: What are the available forms and strengths of P/T?

The official documentation indicates that the medication is supplied as a lyophilized powder for injection in vials. It is available in various strengths that contain different ratios of the two active ingredients. Common vial sizes listed in regulatory documents include 2.25 g, 3.375 g, 4.5 g, and a larger 40.5 g size.


Q: Why is it important to take the medication exactly as prescribed and complete the full course?

Official documentation indicates that the entire prescribed course of therapy should be completed. The official label notes that inconsistent use or not finishing the course is associated with an increased risk of developing resistance to this and other antibacterial drugs.


Q: What should I look for in terms of a rash or other skin changes, and are they dangerous?

The official warnings and precautions section highlights that serious skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. The regulatory documents describe that if a progressive or spreading rash develops, discontinuation of the medication is mandated.


Q: What is the difference between the brand name (Zosyn) and the generic form?

The brand name Zosyn and the generic drug Piperacillin and Tazobactam for injection contain the identical combination of active ingredients. Both are formulated and administered as a powder that must be mixed into a solution for intravenous use.


Q: Does P/T affect fertility or the ability to have children?

Reproduction studies conducted in animals, specifically rats, showed no evidence that the medication caused impaired fertility. Official product information contains a section discussing use in females and males of reproductive potential.


Q: Does P/T affect my blood pressure or heart rate?

Official adverse reaction lists mention hypotension (low blood pressure) as a possible vascular side effect, with an incidence of 1.3% reported in clinical trials. This is one of several possible adverse reactions that can affect the circulatory system, as noted in regulatory documents.


Q: Is P/T approved for mental health conditions like Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD)?

According to the official indications and usage section, this medication is approved only for the treatment of certain severe bacterial infections. These approved uses include specific Intra-abdominal Infections, Pneumonia, Skin Infections, and Female Pelvic Infections.


Q: What are the consequences of stopping treatment early or taking a shorter course than prescribed?

Official information states that stopping treatment early or skipping doses is associated with the possibility that the infection may not be fully eliminated. This action could result in the infection becoming resistant to the medicine, potentially limiting future treatment options.

How should Perota be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines define specific conditions for storing and disposing of Perampanel (often marketed as FYCOMPA).

Storage Conditions:

  • Tablets: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication should be protected from excessive heat, light, and moisture.
  • Oral Suspension: Store the liquid below 30 C (86 F) and do not freeze.
  • Security: As a controlled substance, the medication must be stored securely out of the reach and sight of children to prevent accidental ingestion or misuse.

Stability and Handling:

  • The oral suspension has a limited shelf-life once opened; any unused portion must be discarded 90 days after the bottle is first opened.
  • The suspension should be shaken well before each use.

Disposal Rules:

  • Expired or unused medication, particularly the oral suspension after its 90-day stability period, should be disposed of according to the advice of a healthcare professional or pharmacist, consistent with local federal, state, and local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perota found in:

A-Z Index: